Relmada Therapeutics, Inc.

About Relmada

Addressing areas of high, unmet medical need in the treatment of central nervous system (CNS) diseases.

Overview

We are a clinical stage, publicly traded specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases.

Highlights

Highlights

1 of 5

Robust portfolio of drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain

Highlights

Highlights

2 of 5

Products that combine proven drug candidates with novel delivery methods to create new drugs with new indications, as well as new entities

Highlights

Highlights

3 of 5

A low cost, low risk 505(b)(2) drug development strategy that provides the ability to bring products to market faster

Highlights

Highlights

4 of 5

A risk balanced, therapeutically focused product portfolio mitigates development risk while promising significant upside

Highlights

Highlights

5 of 5

Highly experienced drug development leadership team providing expertise to efficiently advance programs

Product Pipeline

Candidate
(Regulatory Path)
Indication Development Stage
REL-1017
d-Methadone(New Molecular Entity)
Novel NMDA antagonist for the treatment of depression and neuropathic pain
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical Phase 1 Phase 2 Phase 3
REL-1015
LevoCap ER(505(b)(2) regulatory path)
Extended release, abuse resistant form of broad spectrum opioid levorphanol
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical Phase 1 Phase 2 Phase 3
REL-1028
BuTab(505(b)(2) regulatory path)
First traditional oral tablet form of buprenorphine
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical Phase 1 Phase 2 Phase 3
REL-1021
MepiGel(505(b)(2) regulatory path)
Topical gel dosage form of local anesthetic mepivacaine
Preclinical
Phase 1
Phase 2
Phase 3
Preclinical Phase 1 Phase 2 Phase 3

Projected stage of development in 12-24 months

Corporate Strategy

Our strategy is to leverage our considerable industry experience, analgesic therapy knowledge and development expertise to identify, develop and commercialize product candidates with strong market potential that can fulfill unmet medical needs in the treatment of central nervous system (CNS) diseases.

We plan to further develop our new and proprietary drug products to provide improved efficacy, safety and patient convenience primarily using the 505(b)(2) development pathway and develop new indications where use exclusivity is available under the Hatch-Waxman Act, orphan drug regulations and through the generation of IP.  We will continue to prioritize our product development activities after taking into account the resources we have available, market dynamics and potential for value addition.  We will continue to outsource development of our products, while retaining scientific, operational and financial oversight and control.

Leadership

Sandesh Seth, MS, MBA

Chairman

Sandesh Seth is Executive Chairman of Actinium Pharmaceuticals Inc, a biotechnology firm focused on immuno-oncology (radioimmunotherapy). Mr. Seth is the Chairman of Relmada Therapeutics Inc., a specialty pharma company focused on pain…

Charles J. Casamento, MBA

Director

Since 2007 Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group.  He was president and CEO of Osteologix from October 2004 until April 2007. Mr. Casamento was the founder of Questcor…

Paul Kelly, MBA

Director

Paul Kelly has been actively involved as an analyst, consultant and investor in the biotechnology sector for the past twenty years. He began as an equity analyst at Mabon Securities in 1993, and later served in the same capacity at UBS…

Maged Shenouda, R.Ph, MBA

Director

Mr. Shenouda has over 25 years of biotechnology and equity research experience. Most recently, he was head of business development and licensing at Retrophin, Inc. from January 2014 to November 2014. From January 2012 to September 2013, he…

Sergio Traversa, PharmD, MBA

Chief Executive Officer and Interim Chief Financial Officer

Before joining Relmada, Dr. Traversa was the co-founder and CEO of Medeor Inc. a spinoff pharmaceutical company from Cornell University. Dr. Traversa has over twenty-five years of experience in the healthcare sector in the United States…

Richard M. Mangano, PhD

Chief Scientific Officer

Dr. Mangano has extensive experience leading global R&D programs in both large and small pharmaceutical companies including positions in discovery and clinical research at Hoffmann-La Roche, Lederle Laboratories, Wyeth Research and…

Gavril Pasternak, MD, PhD

Andrew Rice, MD, FRCA

Robert H. Dworkin, PhD

Michael E. Thase, MD

James Dolan, MBA